Time to Viral Suppression Does Not Impact SVR in Patients Treated With Gleevec/Pibrentasvir

Christoph Sarrazin1, Jordan Feld2, Douglas S Ely1, Sanjeev Acra1, David Victor3, Yian B Hu4, Stanley Wang5, Federico I Menna4, David Wyler6

1Department of Gastroenterology and Hepatology, University of Colorado School of Medicine, Denver Health Medical Center, Denver, Colorado, United States; 2School of Public Health, University of North Carolina, Chapel Hill, North Carolina, United States; 3Division of Gastroenterology, Hepatology and Nutrition, Northwestern University Feinberg School of Medicine, Chicago, Illinois, United States; 4Department of Medicine, University of Colorado School of Medicine, Denver, Colorado, United States; 5Division of Gastroenterology, Hepatology and Nutrition, University of Colorado School of Medicine, Denver, Colorado, United States; 6Liver and Digestive Diseases, Mayo Clinic, Rochester, Minnesota, United States

**OBJECTIVES**

**INTRODUCTION**

The rapid antiviral response observed with direct-acting antiviral (DAA) regimens has allowed an increase in the proportion of patients with chronic hepatitis C (HCV) infection treated in the community. However, concerns remain that failure to suppress HCV RNA levels during treatment is associated with suboptimal virologic outcomes. This study evaluated factors associated with viral suppression in a large real-world cohort of treatment-naive patients with HCV GT1–6 infection treated with glecaprevir/pibrentasvir (G/P) and evaluated factors impacting time to viral suppression.

**METHODS**

**ENDPOINTS AND ANALYSIS**

**RESULTS**

**CONCLUSIONS**

**REFERENCES**

ACKNOWLEDGEMENTS

**DISCLOSURES**